Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
Executive Summary
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
You may also be interested in...
Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances
FDA-crafted legislative text emerges that generic industry says could weaken the incentive, but so far no changes are in the draft House and Senate bills.
Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances
FDA-crafted legislative text emerges that generic industry says could weaken the incentive, but so far no changes are in the draft House and Senate bills.
180-Day Exclusivity Changes Pushed In Biden’s Budget Proposal
The legislative proposal would make first-filer exclusivity function similar to the competitive generic therapy program, allowing additional approvals if the commercial launch is delayed.